title: Regenerative medicine approach as an alternative treatment to islet transplantation.
abstract: Islet transplantation is considered to be one of the most promising treatment for type I diabetes mellitus (TID). Development of the Edmonton protocol opened the possibility of insulin independence for the patients with TID. However, there is the problem of the donor shortage. Herein we have discussed recent approaches to overcome the problem. It is neccessary to develop a new cellular source for donor islets and to achieve a high engraftment rate. One advantage in TID therapy is that allogeneic islet transplantation is allowed to avoid autoimmunity. That opens broad candidates for the beta-cell source. To achieve a high engraftment rate, is several attempts have sought to develop an appropriate site for transplantation and to modify beta-cells for long-term survival. It is also important to achieve early onset of blood perfusion after transplantation by prevascularization of the islets in vitro. These multiple approaches will bring a milestone in diabetes therapy.
authors.affiliation: Department of Regenerative Medicine, Graduate School of Medicine, Yokohama City University, Yokohama, Kanagawa, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Sekine
authors.forename: T
authors.initials: T
authors.lastname: Takebe
authors.forename: M
authors.initials: M
authors.lastname: Enomura
authors.forename: C
authors.initials: C
authors.lastname: Matsui
authors.forename: H
authors.initials: H
authors.lastname: Tanaka
authors.forename: H
authors.initials: H
authors.lastname: Taniguchi
mesh_terms: D000818:Animals; D002454:Cell Differentiation; D049109:Cell Proliferation; D002470:Cell Survival; D017690:Cell Transplantation / Q000009:adverse effects; D003922:Diabetes Mellitus, Type 1 / Q000473:pathology / Q000503:physiopathology / Q000601:surgery*; D006801:Humans; D007515:Islets of Langerhans / Q000473:pathology / Q000503:physiopathology / Q000601:surgery*; D016381:Islets of Langerhans Transplantation / Q000009:adverse effects; D012038:Regeneration; D044968:Regenerative Medicine / Q000379:methods*; D014019:Tissue Donors / Q000600:supply & distribution*; D016896:Treatment Outcome